41,762 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 41,762 shares of the company’s stock, valued at approximately $1,560,000.

Several other hedge funds have also recently bought and sold shares of BHVN. Ameriprise Financial Inc. increased its holdings in shares of Biohaven by 40.0% in the 4th quarter. Ameriprise Financial Inc. now owns 508,682 shares of the company’s stock valued at $18,994,000 after acquiring an additional 145,331 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in Biohaven by 129.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 106,351 shares of the company’s stock worth $3,972,000 after acquiring an additional 60,000 shares during the period. Bison Wealth LLC lifted its holdings in shares of Biohaven by 0.4% in the 4th quarter. Bison Wealth LLC now owns 332,428 shares of the company’s stock valued at $12,416,000 after buying an additional 1,440 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Biohaven in the 4th quarter valued at approximately $8,456,000. Finally, Northern Trust Corp lifted its holdings in shares of Biohaven by 19.9% in the 4th quarter. Northern Trust Corp now owns 811,155 shares of the company’s stock valued at $30,297,000 after buying an additional 134,879 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Buying and Selling

In other Biohaven news, Director John W. Childs bought 32,700 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the transaction, the director now owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. The trade was a 1.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 16.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their price objective on Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. HC Wainwright restated a “buy” rating and set a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Morgan Stanley decreased their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Robert W. Baird lowered their price target on Biohaven from $60.00 to $57.00 and set an “outperform” rating for the company in a research report on Monday, April 28th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the company a “buy” rating in a research report on Thursday, March 20th. Thirteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average price target of $62.00.

Biohaven Stock Performance

Shares of NYSE:BHVN opened at $16.07 on Monday. The company has a market cap of $1.64 billion, a P/E ratio of -1.72 and a beta of 1.18. The stock’s 50-day moving average is $22.31 and its 200-day moving average is $34.09. Biohaven Ltd. has a 52-week low of $14.69 and a 52-week high of $55.70.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.50). As a group, equities analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.